For the second time this term, the U.S. Supreme Court has asked for the solicitor general’s views on a case involving Section 101 patent eligibility.

The high court issued a series of four controversial decisions on patent eligibility between 2010 and 2014, but has been silent since. The decisions have led to the rejection of thousands of patents, mostly in the software area but quite a few in the biopharma area as well.